Comment on Media Report
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
HAMBURG，德国 / ACCESSWIRE / 2024年11月14日 / Evotec SE（法兰克福证券交易所：EVT）（SDAX/TecDAX，主板，ISIN：DE 000 566480 9，WKN 566480（纳斯达克：EVO）关于媒体报道，Evotec SE（"公司"）宣布收到了列在美国的生物技术公司Halozyme Therapeutics Inc.的非约束性意向表达，内容涉及向公司股东发出的收购要约，每股价格为11.00欧元。公司将认真分析这一意向表达，决定下一步措施，并根据法律要求通知资本市场。
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com
联系人：沃尔克·布劳恩，全球投资者关系及esg负责人，Evotec SE，曼弗雷德·艾根校园，埃塞纳博根7号，22419汉堡，德国，电话：+49 (0) 151 1940 5058（手机），volker.braun@evotec.com
SOURCE: Evotec SE
来源：Evotec SE
